Episode 8 Matt Kaeberlein Part 4 - Ultra-high Dose Rapamycin Case Report 500 -1000 mg Rapamune

Agingdoc Podcast - Agingdoc.com Longevity Coaching and Healthspan Consultation

I do more than just one-on-one longevity coaching at agingdoc.com
I also bring you here on Youtube and on Twitter @agingdoc1 interesting content pertinent to aging biology, healthy aging, longevity, lifestyle medicine, and more.
The video version of this podcast, highly recommended, especially for the first two minutes can be found on YouTube at: https://youtu.be/62nDXSebMoY
Come join me by registering for my NUS lecture including Q&A livestream,
Jan 20, 2024 06:30 AM in EST (with free question and answer Q & A with reigstration)
http://tinyurl.com/yck5x457
https://nus-sg.zoom.us/webinar/register/WN_MPlVUaMiScC_GNh0YIi5sA#/registration
This episode, Matt Kaeberlein PhD and I discuss case reports by anonymous N1 (validated by myself, "Agingdoc"). In the previous episode generic rapamune dose of 180 mg was discussed.
Don't miss extensive rapamycin episode 7 refs /notes at:
http://agingdoc.com/rapamycin
Today's episode discusses 100 mg generic Rapamune for an effective dose dose of ~500 mg. Subsequent to recording N1 doubled the dose to 200 mg for an effective dose of 1,000 mg which is approximately 100 - 150 x the most common off-label weekly dosing of rapamycin.
Potentially life-threatening opportunistic infections is one of a number established serious risks associated with high dose rapamcyin dosing regimens. Should an individual develop a serious infection, systemic rapamycin may worsen prognosis and would be slow to be eliminated during a critical window of the infection.
We contrast with prior work by Joan Mannick examining the affect of closely related rapalog everolimus on vaccination immunization, N1 obtained a COVID vaccine booster within 12 hours of a dose of sirolimus of 20 mg.
Counter to the hypothesis that a washout is necessary for vaccine amplification N1 had a strong booster effect as judged by titers.
N1 also experienced cardiologist confirmed peri- & myocarditis associated with the COVID booster. Whether sirolimus was contributory or alternatively ameliorated it remains a matter of speculation.
While these results cannot be generalized "the exception breaks the rule, and these cases are fodder for hypotheses generation.
1. Pharmacotherapy effectively maintained normal lipid and glucose levels.
2. High dose physiologically possible in at least one human
In the context of an academic institution sponsored randomized controlled may be considered, particularly if tissue saturation is more challenging (say, protected areas like the brain or the setting of cancer).
3. Suggestive washout may not be needed ResTORbio everolimus immunization RCT protocol, but with no or else a shorter washout period than they employed.
Over 200 ng/mL sirolimus Cmax is the highest I have seen in the setting of Rapamune, but also not as high as one may expect. It may be that elimination is more efficient in humans.
Rapamycin extends lifespan or healthspan used off-label in healthy humans, but by contrast significant risk exists. Rigorous evaluation for off-label indications in

Links:
Agingdoc.com ( More info & Longevity Coaching scheduling)
Agingdoc Podcast on Youtube (Video)
Agingdoc on X (Posts of health articles: some good, some bad, but eclectic & interesting)
Agingdoc Longevity Tech interview (about my "big reveal")
Lifespan.io talks to Agingdoc
Youtube Video Bio - As guest on The Sheekey Science Show.